Advertisement

Chronic Pain and Opioids

  • Martin D. CheatleEmail author
  • Rollin M. Gallagher
Chapter

Abstract

The medical community for the treatment of acute, surgical, and cancer-related pain has long accepted opioid analgesics. Over the past several decades, this acute and cancer-related opioid therapy model for pain control was expanded to include chronic nonmalignant pain conditions. While it has been highly debated as to the long-term efficacy of opioid therapy for chronic pain, there is evidence that opioids can be effective in the treatment of chronic pain in a subgroup of individuals. However, there are certain risks associated with the long-term use of opioid analgesics. The prescribing clinician must consider not only common adverse effect of this class of medications but also the unique adverse effects associated with long-term opioid administration including the risk of misuse, abuse, and developing an opioid use disorder (OUD). The risks and benefits of prescribing opioids must be carefully weighed for each chronic pain patient. This chapter will provide a review of the risks and benefits of using opioid analgesics in the treatment of chronic pain. Potential problems associated with opioid therapy are addressed, and various strategies to manage these problems are included.

References

  1. Abs, R., Verhelst, J., Maeyaert, J., Van Buyten, J. P., Opsomer, F., et al. (2000). Endocrine consequences of long-term intrathecal administration of opioids. The Journal of Clinical Endocrinology and Metabolism, 85, 2215–2222.PubMedCrossRefGoogle Scholar
  2. Agency for Health Care Quality and Research. (1992a). Acute pain management: Operative or medical procedures and trauma, part 1. Clinical Pharmacy, 11, 309–331.Google Scholar
  3. Agency for Health Care Quality and Research. (1992b). Acute pain management: Operative or medical procedures and trauma, part 2. Clinical Pharmacy, 11, 391–414.Google Scholar
  4. Aiyer, R., Gulati, A., Gungor, S., Bhatia, A., & Mehta, N. (2017, December 11). Treatment of chronic pain with various buprenorphine formulations: A systematic review of clinical studies. Anesthesia and Analgesia.  https://doi.org/10.1213/ANE.0000000000002718.CrossRefGoogle Scholar
  5. Ali, K., Raphael, J., Khan, S., Labib, M., & Duarte, R. (2016, September 19). The effects of opioids on the endocrine system: An overview. Postgraduate Medical Journal.  https://doi.org/10.1136/postgradmedj-2016-134299.PubMedCrossRefGoogle Scholar
  6. Amabile, C. M., & Bowman, B. J. (2006). Overview of oral modified-release opioid products for the management of chronic pain. The Annals of Pharmacotherapy, 40, 1327–1335.PubMedCrossRefGoogle Scholar
  7. American Pain Society. (2001). Definitions related to the use of opioids for the treatment of pain. A consensus document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine. I. Glenview, The American Academy of Pain Medicine 2001.Google Scholar
  8. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: American Psychiatric Association.CrossRefGoogle Scholar
  9. Apkarian, A. V., Sosa, Y., Sonty, S., Levy, R. M., Harden, R. N., et al. (2004). Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. The Journal of Neuroscience, 24, 10410–10415.PubMedCrossRefGoogle Scholar
  10. Arnold, L. M., Hudson, J. I., Hess, E. V., Ware, A. E., Fritz, D. A., et al. (2004). Family study of fibromyalgia. Arthritis and Rheumatism, 50, 944–952.PubMedCrossRefGoogle Scholar
  11. Askitopoulou, H., Ramoutsaki, I. A., & Konsolaki, E. (2002). Archaeological evidence on the use of opium in the Minoan world. International Congress Series, 1292, 23–97.CrossRefGoogle Scholar
  12. Asmundson, G. J., & Katz, J. (2009). Understanding the co-occurrence of anxiety disorders and chronic pain: State-of-the-art. Depression and Anxiety, 26, 888–901.PubMedCrossRefGoogle Scholar
  13. Asmundson, G. J., Coons, M. J., Taylor, S., & Katz, J. (2002). PTSD and the experience of pain: Research and clinical implications of shared vulnerability and mutual maintenance models. Canadian Journal of Psychiatry, 47, 930–937.PubMedCrossRefGoogle Scholar
  14. Baile, C. A., McLaughlin, C. L., & Della-Fera, M. A. (1986). Role of cholecystokinin and opioid peptides in control of food intake. Physiological Reviews, 66, 172–234.PubMedCrossRefGoogle Scholar
  15. Bailey, C. J., & Flatt, P. R. (1987). Increased responsiveness to glucoregulatory effect of opiates in obese-diabetic ob/ob mice. Diabetologia, 30, 33–37.PubMedCrossRefGoogle Scholar
  16. Baliki, M. N., Chialvo, D. R., Geha, P. Y., Levy, R. M., Harden, R. N., et al. (2006). Chronic pain and the emotional brain: Specific brain activity associated with spontaneous fluctuations of intensity of chronic back pain. The Journal of Neuroscience, 26, 12165–12173.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Baliki, M. N., Geha, P. Y., Apkarian, A. V., & Chialvo, D. R. (2008). Beyond feeling: Chronic pain hurts the brain, disrupting the default-mode network dynamics. The Journal of Neuroscience, 28, 1398–1403.PubMedCrossRefGoogle Scholar
  18. Ballantyne, J. C. (2007). Opioid analgesia: Perspectives on right use and utility. Pain Physician, 10, 479–491.PubMedGoogle Scholar
  19. Beaver, W. T., Wallenstein, S. L., Houde, R. W., & Rogers, A. (1967). A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly, and of orally and parenterally administered methadone. Clinical Pharmacology and Therapeutics, 8, 415–426.PubMedCrossRefGoogle Scholar
  20. Bederson, J. B., Fields, H. L., & Barbaro, N. M. (1990). Hyperalgesia during naloxone-precipitated withdrawal from morphine is associated with increased on-cell activity in the rostral ventromedial medulla. Somatosensory and Motor Research, 7, 185–203.PubMedCrossRefGoogle Scholar
  21. Belgrade, M. J., Schamber, C. D., & Lindgren, B. R. (2006). The DIRE score: Predicting outcomes of opioid prescribing for chronic pain. The Journal of Pain, 7, 671–681.PubMedCrossRefGoogle Scholar
  22. Blick, G., Khera, M., Bhattacharya, R. K., Nguyen, D., Kushner, H., & Miner, M. M. (2012, May). Testosterone replacement therapy outcomes among opioid users: The Testim Registry in the United States (TRiUS). Pain Medicine, 13(5), 688–698.PubMedCrossRefGoogle Scholar
  23. Bliesener, N., Albrecht, S., Schwager, A., Weckbecker, K., Lichtermann, D., et al. (2005). Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. The Journal of Clinical Endocrinology and Metabolism, 90, 203–206.PubMedCrossRefGoogle Scholar
  24. Bohnert, A. S., Valenstein, M., Bair, M. J., Ganoczy, D., McCarthy, J. F., Ilgen, M. A., & Blow, F. C. (2011, April 6). Association between opioid prescribing patterns and opioid overdose-related deaths. Journal of the American Medical Association, 305(13), 1315–1321.PubMedCrossRefGoogle Scholar
  25. Booth, M. (1986). Opium: A history. New York, NY: St. Martin’s Press.Google Scholar
  26. Boscarino, J. A., Rukstalis, M. R., Hoffman, S. N., Han, J. J., Erlich, P. M., Ross, S., Gerhard, G. S., & Stewart, W. F. (2011). Prevalence of prescription opioid-use disorder among chronic pain patients: Comparison of the DSM-5 vs. DSM-4 diagnostic criteria. Journal of Addictive Diseases, 30(3), 185–194.PubMedCrossRefGoogle Scholar
  27. Boscarino, J. A., Hoffman, S. N., & Han, J. J. (2015, August 19). Opioid-use disorder among patients on long-term opioid therapy: Impact of final DSM-5 diagnostic criteria on prevalence and correlates. Substance Abuse and Rehabilitation, 6, 83–91.PubMedPubMedCentralCrossRefGoogle Scholar
  28. Buckalew, N., Haut, M. W., Aizenstein, H., Morrow, L., Perera, S., et al. (2010). Differences in brain structure and function in older adults with self-reported disabling and nondisabling chronic low back pain. Pain Medicine, 11, 1183–1197.PubMedCrossRefGoogle Scholar
  29. Butler, S. F., Budman, S. H., Fernandez, K. C., Houle, B., Benoit, C., et al. (2007). Development and validation of the Current Opioid Misuse Measure. Pain, 130, 144–156.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Butler, S. F., Fernandez, K., Benoit, C., Budman, S. H., & Jamison, R. N. (2008). Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). The Journal of Pain, 9, 360–372.PubMedPubMedCentralCrossRefGoogle Scholar
  31. Celerier, E., Rivat, C., Jun, Y., Laulin, J. P., Larcher, A., et al. (2000). Long-lasting hyperalgesia induced by fentanyl in rats: Preventive effect of ketamine. Anesthesiology, 92, 465–472.PubMedCrossRefGoogle Scholar
  32. Chang, G., Chen, L., & Mao, J. (2007). Opioid tolerance and hyperalgesia. The Medical Clinics of North America, 91, 199–211.PubMedCrossRefGoogle Scholar
  33. Chaparro, L. E., Furlan, A. D., Deshpande, A., Mailis-Gagnon, A., Atlas, S., & Turk, D. C. (2013). Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database of Systematic Reviews, (8), CD004959.  https://doi.org/10.1002/14651858.CD004959.pub4.
  34. Cheatle, M. D. (2016a, January). Biopsychosocial approach to assessing and managing patients with chronic pain. The Medical Clinics of North America, 100(1), 43–53.PubMedCrossRefGoogle Scholar
  35. Cheatle, M. D. (2016b, June). Facing the challenge of pain management and opioid misuse, abuse and opioid-related fatalities. Expert Review of Clinical Pharmacology, 9(6), 751–754.PubMedCrossRefGoogle Scholar
  36. Cheatle, M. D., & O’Brien, C. P. (2011). Opioid therapy in patients with chronic noncancer pain: Diagnostic and clinical challenges. Advances in Psychosomatic Medicine, 30, 61–69.PubMedCrossRefGoogle Scholar
  37. Cheatle, M. D., & Savage, S. R. (2012, July). Informed consent in opioid therapy: A potential obligation and opportunity. Journal of Pain and Symptom Management, 44(1), 105–116.PubMedPubMedCentralCrossRefGoogle Scholar
  38. Cheatle, M., Comer, D., Wunsch, M., Skoufalos, A., & Reddy, Y. (2014, April). Treating pain in addicted patients: Recommendations from an expert panel. Population Health Management, 17(2), 79–89.PubMedPubMedCentralCrossRefGoogle Scholar
  39. Cheatle, M. D., Gallagher, R. M., & O’Brien, C. P. (2018, April 1). Low risk of producing an opioid use disorder in primary care by prescribing opioids to prescreened patients with chronic noncancer pain. Pain Medicine, 19(4), 764–773.PubMedCrossRefGoogle Scholar
  40. Chen, L. H., Hedegaard, H., & Warner, M. (2014, September). Drug-poisoning deaths involving opioid analgesics: United States, 1999-2011. NCHS Data Brief, 166, 1–8.Google Scholar
  41. Chiou, L. C., Liao, Y. Y., Fan, P. C., Kuo, P. H., Wang, C. H., et al. (2007). Nociceptin/orphanin FQ peptide receptors: Pharmacology and clinical implications. Current Drug Targets, 8, 117–135.PubMedCrossRefGoogle Scholar
  42. Chou, R., Fanciullo, G. J., Fine, P. G., Adler, J. A., Ballantyne, J. C., et al. (2009). Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. The Journal of Pain, 10, 113–130.PubMedPubMedCentralCrossRefGoogle Scholar
  43. Chou, R., Turner, J. A., Devine, E. B., Hansen, R. N., Sullivan, S. D., Blazina, I., Dana, T., Bougatsos, C., & Deyo, R. A. (2015, February 17). The effectiveness and risks of long-term opioid therapy for chronic pain: A systematic review for a National Institutes of Health Pathways to Prevention Workshop. Annals of Internal Medicine, 162(4), 276–286.PubMedCrossRefGoogle Scholar
  44. Christie, M. J. (2008). Cellular neuroadaptations to chronic opioids: Tolerance, withdrawal and addiction. British Journal of Pharmacology, 154, 384–396.PubMedPubMedCentralCrossRefGoogle Scholar
  45. Chu, L. F., Clark, D. J., & Angst, M. S. (2006). Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: A preliminary prospective study. The Journal of Pain, 7, 43–48.PubMedCrossRefGoogle Scholar
  46. Chugh, S. S., Socoteanu, C., Reinier, K., Waltz, J., Jui, J., et al. (2008). A community-based evaluation of sudden death associated with therapeutic levels of methadone. The American Journal of Medicine, 121, 66–71.PubMedPubMedCentralCrossRefGoogle Scholar
  47. Cicero, T. J., & Ellis, M. S. (2015, May). Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: Lessons learned from OxyContin. JAMA Psychiatry, 72(5), 424–430.PubMedCrossRefGoogle Scholar
  48. Cicero, T. J., Ellis, M. S., Harney, J. (2015, Oct). Shifting patterns of prescription opioid and heroin abuse in the United States. N Engl J Med, 373(18), 1789–90.PubMedCrossRefGoogle Scholar
  49. Compton, P., Darakjian, J., & Miotto, K. (1998). Screening for addiction in patients with chronic pain and “problematic” substance use: Evaluation of a pilot assessment tool. Journal of Pain and Symptom Management, 16, 355–363.PubMedCrossRefGoogle Scholar
  50. Compton, P., Charuvastra, V. C., & Ling, W. (2001). Pain intolerance in opioid-maintained former opiate addicts: Effect of long-acting maintenance agent. Drug and Alcohol Dependence, 63, 139–146.PubMedCrossRefGoogle Scholar
  51. Cook, R. F., Bernstein, A. D., Arrington, T. L., Andrews, C. M., & Marshall, G. A. (1995). Methods for assessing drug use prevalence in the workplace: A comparison of self-report, urinalysis, and hair analysis. The International Journal of the Addictions, 30, 403–426.PubMedCrossRefGoogle Scholar
  52. Cowan, D. T., Wilson-Barnett, J., Griffiths, P., Vaughan, D. J., Gondhia, A., et al. (2005). A randomized, double-blind, placebo-controlled, cross-over pilot study to assess the effects of long-term opioid drug consumption and subsequent abstinence in chronic noncancer pain patients receiving controlled-release morphine. Pain Medicine, 6, 113–121.PubMedCrossRefGoogle Scholar
  53. Cruciani, R. A., Sekine, R., Homel, P., Lussier, D., Yap, Y., et al. (2005). Measurement of QTc in patients receiving chronic methadone therapy. Journal of Pain and Symptom Management, 29, 385–391.PubMedCrossRefGoogle Scholar
  54. Daniell, H. W. (2002). Hypogonadism in men consuming sustained-action oral opioids. The Journal of Pain, 3, 377–384.PubMedCrossRefGoogle Scholar
  55. Daniell, H. W. (2006). Opioid-induced androgen deficiency. Current Opinion in Endocrinology Diabetes and Obesity, 13, 262–266.CrossRefGoogle Scholar
  56. Daniell, H. W. (2008). Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. The Journal of Pain, 9, 28–36.PubMedCrossRefGoogle Scholar
  57. Daniell, H. W., Lentz, R., & Mazer, N. A. (2006). Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. The Journal of Pain, 7, 200–210.PubMedCrossRefGoogle Scholar
  58. Dart, R. C., Severtson, S. G., & Bucher-Bartelson, B. (2015, April 16). Trends in opioid analgesic abuse and mortality in the United States. The New England Journal of Medicine, 372(16), 1573–1574.PubMedGoogle Scholar
  59. Dean, J. D., Carnegie, C., Rodzvilla, J., & Smith, T. (2005). Long-term effects of testim(r) 1% testosterone gel in hypogonadal men. Revista de Urología, 7(2), 87–94.Google Scholar
  60. Dieleman, J. L., Baral, R., Birger, M., Bui, A. L., Bulchis, A., Chapin, A., Hamavid, H., Horst, C., Johnson, E. K., Joseph, J., Lavado, R., Lomsadze, L., Reynolds, A., Squires, E., Campbell, M., DeCenso, B., Dicker, D., Flaxman, A. D., Gabert, R., Highfill, T., Naghavi, M., Nightingale, N., Templin, T., Tobias, M. I., Vos, T., Murray, C. J. (2016). US Spending on Personal Health Care and Public Health, 1996–2013. JAMA. 316(24), 2627–2646.PubMedPubMedCentralCrossRefGoogle Scholar
  61. Dikotter, F., Laaman, L., & Xun, Z. (2004). Narcotic culture: A history of drugs in China. Chicago, IL: University of Chicago Press.Google Scholar
  62. Dogrul, A., Bilsky, E. J., Ossipov, M. H., Lai, J., & Porreca, F. (2005). Spinal L-type calcium channel blockade abolishes opioid-induced sensory hypersensitivity and antinociceptive tolerance. Anesthesia and Analgesia, 101, 1730–1735.PubMedCrossRefGoogle Scholar
  63. Dohrenwend, B. P., Raphael, K. G., Marbach, J. J., & Gallagher, R. M. (1999). Why is depression comorbid with chronic myofascial face pain? A family study test of alternative hypotheses. Pain, 83, 183–192.PubMedCrossRefGoogle Scholar
  64. Dowell, D., Haegerich, T. M., & Chou, R. (2016, March 18). CDC guideline for prescribing opioids for chronic pain – United States, 2016. MMWR – Recommendations and Reports, 65(1), 1–49.PubMedCrossRefGoogle Scholar
  65. Edlund, M. J., Steffick, D., Hudson, T., Harris, K. M., & Sullivan, M. (2007). Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain, 129, 355–362.PubMedCrossRefGoogle Scholar
  66. Eisendrath, S. J. (1995). Psychiatric aspects of chronic pain. Neurology, 45, S26–S34; discussion S35–S36.PubMedCrossRefGoogle Scholar
  67. Els, C., Jackson, T. D., Hagtvedt, R., Kunyk, D., Sonnenberg, B., Lappi, V. G., & Straube, S. (2017, October 30). High-dose opioids for chronic non-cancer pain: An overview of Cochrane reviews. Cochrane Database of Systematic Reviews, 10, CD012299.PubMedGoogle Scholar
  68. Epstein, D. H., Preston, K. L., & Jasinski, D. R. (2006). Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: Lessons from tramadol. Biological Psychology, 73, 90–99.PubMedPubMedCentralCrossRefGoogle Scholar
  69. Fishbain, D. A. (1999). Approaches to treatment decisions for psychiatric comorbidity in the management of the chronic pain patient. Medical Clinics of North America, 83, 737–760, vii.CrossRefGoogle Scholar
  70. Fishbain, D. A., Rosomoff, H. L., & Rosomoff, R. S. (1992). Drug abuse, dependence, and addiction in chronic pain patients. The Clinical Journal of Pain, 8, 77–85.CrossRefGoogle Scholar
  71. Fishbain, D. A., Cutler, R. B., Rosomoff, H. L., & Rosomoff, R. S. (1999). Validity of self-reported drug use in chronic pain patients. The Clinical Journal of Pain, 15, 184–191.PubMedCrossRefGoogle Scholar
  72. Fishbain, D. A., Cole, B., Lewis, J. E., Gao, J., & Rosomoff, R. S. (2009). Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Medicine, 10, 829–839.PubMedCrossRefGoogle Scholar
  73. Fishman, S. M., Carr, D. B., Hogans, B., Cheatle, M., Gallagher, R. M., Katzman, J., Mackey, S., Polomano, R., Popescu, A., Rathmell, J. P., Rosenquist, R. W., Tauben, D., Beckett, L., Li, Y., Mongoven, J. M., & Young, H. M. (2018, March 1). Scope and nature of pain- and analgesia-related content of the United States Medical Licensing Examination (USMLE). Pain Medicine, 19(3), 449–459.PubMedCrossRefGoogle Scholar
  74. Fleming, M. F., Davis, J., & Passik, S. D. (2008). Reported lifetime aberrant drug-taking behaviors are predictive of current substance use and mental health problems in primary care patients. Pain Medicine, 9, 1098–1106.PubMedCrossRefGoogle Scholar
  75. Flor, H., Fydrich, T., & Turk, D. C. (1992). Efficacy of multidisciplinary pain treatment centers: A meta-analytic review. Pain, 49, 221–230.CrossRefGoogle Scholar
  76. Foley, K. M., & Houde, R. W. (1998). Methadone in cancer pain management: Individualize dose and titrate to effect. Journal of Clinical Oncology, 16, 3213–3215.PubMedCrossRefGoogle Scholar
  77. Fraser, L. A., Morrison, D., Morley-Forster, P., Paul, T. L., Tokmakejian, S., et al. (2009). Oral opioids for chronic non-cancer pain: Higher prevalence of hypogonadism in men than in women. Experimental and Clinical Endocrinology & Diabetes, 117, 38–43.CrossRefGoogle Scholar
  78. Fredheim, O. M., Borchgrevink, P. C., Hegrenaes, L., Kaasa, S., Dale, O., et al. (2006a). Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: A prospective 9-month follow-up study. Journal of Pain and Symptom Management, 32, 180–185.PubMedCrossRefGoogle Scholar
  79. Fredheim, O. M., Kaasa, S., Dale, O., Klepstad, P., Landro, N. I., et al. (2006b). Opioid switching from oral slow release morphine to oral methadone may improve pain control in chronic non-malignant pain: A nine-month follow-up study. Palliative Medicine, 20, 35–41.PubMedCrossRefGoogle Scholar
  80. Freye, E., Anderson-Hillemacher, A., Ritzdorf, I., & Levy, J. V. (2007). Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain Practice, 7, 123–129.PubMedCrossRefGoogle Scholar
  81. Gagajewski, A., & Apple, F. S. (2003). Methadone-related deaths in Hennepin County, Minnesota: 1992–2002. Journal of Forensic Sciences, 48, 668–671.PubMedCrossRefGoogle Scholar
  82. Galer, B. S., Coyle, N., Pasternak, G. W., & Portenoy, R. K. (1992). Individual variability in the response to different opioids: Report of five cases. Pain, 49, 87–91.PubMedCrossRefGoogle Scholar
  83. Gallagher, R. M. (2004). Biopsychosocial pain medicine and mind-brain-body science. Physical Medicine and Rehabilitation Clinics of North America, 15, 855–882, vii.PubMedCrossRefGoogle Scholar
  84. Gallagher, R. M., & Rosenthal, L. J. (2008). Chronic pain and opiates: Balancing pain control and risks in long-term opioid treatment. Archives of Physical Medicine and Rehabilitation, 89, S77–S82.PubMedCrossRefGoogle Scholar
  85. Gallagher, R. M., & Verma, S. (1999). Managing pain and comorbid depression: A public health challenge. Seminars in Clinical Neuropsychiatry, 4, 203–220.PubMedGoogle Scholar
  86. Gallagher, R. M., Marbach, J. J., Raphael, K. G., Handte, J., & Dohrenwend, B. P. (1995). Myofascial face pain: Seasonal variability in pain intensity and demoralization. Pain, 61, 113–120.PubMedCrossRefGoogle Scholar
  87. Gallagher, R. M., Verma, S., & Mossey, J. (2000). Chronic pain. Sources of late-life pain and risk factors for disability. Geriatrics, 55, 40–44, 47.PubMedGoogle Scholar
  88. Gardell, L. R., Wang, R., Burgess, S. E., Ossipov, M. H., Vanderah, T. W., et al. (2002). Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. The Journal of Neuroscience, 22, 6747–6755.PubMedCrossRefGoogle Scholar
  89. Gatti, A., Reale, C., Luzi, M., Canneti, A., Mediati, R. D., et al. (2010). Effects of opioid rotation in chronic pain patients: ORTIBARN study. Clinical Drug Investigation, 30(Suppl 2), 39–47.PubMedCrossRefGoogle Scholar
  90. Geisser, M. E., Robinson, M. E., Miller, Q. L., & Bade, S. M. (2003). Psychosocial factors and functional capacity evaluation among persons with chronic pain. Journal of Occupational Rehabilitation, 13, 259–276.PubMedCrossRefGoogle Scholar
  91. Giesecke, T., Gracely, R. H., Williams, D. A., Geisser, M. E., Petzke, F. W., et al. (2005). The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis and Rheumatism, 52, 1577–1584.PubMedCrossRefGoogle Scholar
  92. Gillen, C., Haurand, M., Kobelt, D. J., & Wnendt, S. (2000). Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn-Schmiedeberg’s Archives of Pharmacology, 362, 116–121.PubMedCrossRefGoogle Scholar
  93. Gimbel, J., Spierings, E. L., Katz, N., Xiang, Q., Tzanis, E., & Finn, A. (2016). Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: Results of a phase 3, enriched enrollment, randomized withdrawal study. Pain, 157, 2517–2526.PubMedPubMedCentralCrossRefGoogle Scholar
  94. Giugliano, D. (1984). Morphine, opioid peptides, and pancreatic islet function. Diabetes Care, 7, 92–98.PubMedCrossRefGoogle Scholar
  95. Gomez-Flores, R., & Weber, R. J. (2000). Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray. Immunopharmacology, 48, 145–156.PubMedCrossRefGoogle Scholar
  96. Gonzalez-Barboteo, J., Porta-Sales, J., Sanchez, D., Tuca, A., & Gomez-Batiste, X. (2008). Conversion from parenteral to oral methadone. Journal of Pain & Palliative Care Pharmacotherapy, 22, 200–205.CrossRefGoogle Scholar
  97. Gordon, D. B., Dahl, J., Phillips, P., Frandsen, J., Cowley, C., et al. (2004). The use of “as-needed” range orders for opioid analgesics in the management of acute pain: A consensus statement of the American Society for Pain Management Nursing and the American Pain Society. Pain Management Nursing, 5, 53–58.PubMedCrossRefGoogle Scholar
  98. Gourlay, D. L., Heit, H. A., & Almahrezi, A. (2005). Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Medicine, 6, 107–112.CrossRefGoogle Scholar
  99. Gressler, L. E., Hammond, D. A., & Painter, J. T. (2017, September–December). Serotonin syndrome in tapentadol literature: Systematic review of original research. Journal of Pain & Palliative Care Pharmacotherapy, 31(3–4), 228–236.CrossRefGoogle Scholar
  100. Grond, S., & Sablotzki, A. (2004). Clinical pharmacology of tramadol. Clinical Pharmacokinetics, 43, 879–923.PubMedCrossRefGoogle Scholar
  101. Grosen, K., Olesen, A. E., Gram, M., Jonsson, T., Kamp-Jensen, M., Andresen, T., Nielsen, C., Pozlep, G., Pfeiffer-Jensen, M., Morlion, B., & Drewes, A. M. (2017, February 3). Predictors of opioid efficacy in patients with chronic pain: A prospective multicenter observational cohort study. PLoS One, 12(2), e0171723.PubMedPubMedCentralCrossRefGoogle Scholar
  102. Guignard, B., Bossard, A. E., Coste, C., Sessler, D. I., Lebrault, C., et al. (2000). Acute opioid tolerance: Intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology, 93, 409–417.PubMedCrossRefGoogle Scholar
  103. Guststein, H. B., & Akil, H. (2006). Opioid analgesics. In L. L. Brunton, J. S. Lazo, & K. L. Parker (Eds.), Goodman and Gilman’s the pharmacological basis of therapeutics (11th ed., pp. 547–590). New York, NY: McGraw-Hill Medical.Google Scholar
  104. Guzman, J., Esmail, R., Karjalainen, K., Malmivaara, A., Irvin, E., et al. (2001). Multidisciplinary rehabilitation for chronic low back pain: Systematic review. British Medical Journal, 322, 1511–1516.PubMedCrossRefGoogle Scholar
  105. Hallinan, R., Byrne, A., Agho, K., McMahon, C., Tynan, P., et al. (2008). Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. The Journal of Sexual Medicine, 5, 684–692.PubMedCrossRefGoogle Scholar
  106. Han, W., Ide, S., Sora, I., Yamamoto, H., & Ikeda, K. (2004). A possible genetic mechanism underlying individual and interstrain differences in opioid actions: Focus on the mu opioid receptor gene. Annals of the New York Academy of Sciences, 1025, 370–375.PubMedCrossRefGoogle Scholar
  107. Heit, H. A. (2003). Addiction, physical dependence, and tolerance: Precise definitions to help clinicians evaluate and treat chronic pain patients. Journal of Pain & Palliative Care Pharmacotherapy, 17(1), 15–29.Google Scholar
  108. Heit, H. A., & Gourlay, D. L. (2008). Buprenorphine: New tricks with an old molecule for pain management. The Clinical Journal of Pain, 24, 93–97.PubMedCrossRefGoogle Scholar
  109. Hoffman, B. M., Papas, R. K., Chatkoff, D. K., & Kerns, R. D. (2007). Meta-analysis of psychological interventions for chronic low back pain. Health Psychology, 26, 1–9.CrossRefGoogle Scholar
  110. Institute of Medicine (IOM). (2011). Relieving pain in America: A blueprint for transforming prevention, care, education, and research: A call for public action. Washington, DC: The National Academies Press.Google Scholar
  111. Inturrisi, C. E. (2002). Clinical pharmacology of opioids for pain. The Clinical Journal of Pain, 18, S3–S13.PubMedCrossRefGoogle Scholar
  112. Ives, T. J., Chelminski, P. R., Hammett-Stabler, C. A., Malone, R. M., Perhac, J. S., et al. (2006). Predictors of opioid misuse in patients with chronic pain: A prospective cohort study. BMC Health Services Research, 6, 46.PubMedPubMedCentralCrossRefGoogle Scholar
  113. Jones, C. M., Mack, K. A., & Paulozzi, L. J. (2013, February 20). Pharmaceutical overdose deaths, United States, 2010. Journal of the American Medical Association, 309(7), 657–659.PubMedCrossRefGoogle Scholar
  114. Jovey, R. D., Ennis, J., Gardner-Nix, J., Goldman, B., Hays, H., et al. (2003). Use of opioid analgesics for the treatment of chronic noncancer pain: A consensus statement and guidelines from the Canadian Pain Society, 2002. Pain Research & Management, 8(Suppl A), 3A–28A.CrossRefGoogle Scholar
  115. Kalso, E., Edwards, J. E., Moore, R. A., & McQuay, H. J. (2004). Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain, 112, 372–380.PubMedCrossRefGoogle Scholar
  116. Kanner, R. M., & Foley, K. M. (1981). Patterns of narcotic drug use in a cancer pain clinic. Annals of the New York Academy of Sciences, 362, 161–172.PubMedCrossRefGoogle Scholar
  117. Kaplan, H., & Fields, H. L. (1991). Hyperalgesia during acute opioid abstinence: Evidence for a nociceptive facilitating function of the rostral ventromedial medulla. The Journal of Neuroscience, 11, 1433–1439.PubMedCrossRefGoogle Scholar
  118. Karam, G. A., Reisi, M., Kaseb, A. A., Khaksari, M., Mohammadi, A., et al. (2004). Effects of opium addiction on some serum factors in addicts with non-insulin-dependent diabetes mellitus. Addiction Biology, 9, 53–58.PubMedCrossRefGoogle Scholar
  119. Karci, A., Tasdogen, A., Erkin, Y., Aktas, G., & Elar, Z. (2004). The analgesic effect of morphine on postoperative pain in diabetic patients. Acta Anaesthesiologica Scandinavica, 48, 619–624.PubMedCrossRefGoogle Scholar
  120. Katz, N., & Fanciullo, G. J. (2002). Role of urine toxicology testing in the management of chronic opioid therapy. The Clinical Journal of Pain, 18, S76–S82.PubMedCrossRefGoogle Scholar
  121. Katz, N. P., Sherburne, S., Beach, M., Rose, R. J., Vielguth, J., et al. (2003). Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesthesia and Analgesia, 97, 1097–1102, table of contents.PubMedCrossRefGoogle Scholar
  122. Katznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996, December). Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. The Journal of Clinical Endocrinology and Metabolism, 81(12), 4358–4365.PubMedGoogle Scholar
  123. King, T., Gardell, L. R., Wang, R., Vardanyan, A., Ossipov, M. H., et al. (2005). Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain, 116, 276–288.PubMedPubMedCentralCrossRefGoogle Scholar
  124. Kinjo, M., Setoguchi, S., Schneeweiss, S., & Solomon, D. H. (2005). Bone mineral density in subjects using central nervous system-active medications. The American Journal of Medicine, 118, 1414.PubMedCrossRefGoogle Scholar
  125. Koch, T., & Hollt, V. (2008). Role of receptor internalization in opioid tolerance and dependence. Pharmacology and Therapeutics, 117, 199–206.PubMedCrossRefGoogle Scholar
  126. Krantz, M. J., Lewkowiez, L., Hays, H., Woodroffe, M. A., Robertson, A. D., et al. (2002). Torsade de pointes associated with very-high-dose methadone. Annals of Internal Medicine, 137, 501–504.PubMedCrossRefGoogle Scholar
  127. Krebs, E. E., Gravely, A., Nugent, S., Jensen, A. C., DeRonne, B., Goldsmith, E. S., Kroenke, K., Bair, M. J., & Noorbaloochi, S. (2018, March 6). Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: The SPACE randomized clinical trial. Journal of the American Medical Association, 319(9), 872–882.PubMedCrossRefGoogle Scholar
  128. Kreek, M. J. (2001). Drug addictions. Molecular and cellular endpoints. Annals of the New York Academy of Sciences, 937, 27–49.PubMedCrossRefGoogle Scholar
  129. Kulkarni, B., Bentley, D. E., Elliott, R., Julyan, P. J., Boger, E., et al. (2007). Arthritic pain is processed in brain areas concerned with emotions and fear. Arthritis and Rheumatism, 56, 1345–1354.PubMedCrossRefGoogle Scholar
  130. Lafisca, S., Bolelli, G., Franceschetti, F., Danieli, A., Tagliaro, F., et al. (1985). Free and bound testosterone in male heroin addicts. Archives of Toxicology Supplement, 8, 394–397.CrossRefGoogle Scholar
  131. Langleben, D. D., Ruparel, K., Elman, I., Busch-Winokur, S., Pratiwadi, R., et al. (2008). Acute effect of methadone maintenance dose on brain FMRI response to heroin-related cues. The American Journal of Psychiatry, 165, 390–394.PubMedCrossRefGoogle Scholar
  132. Laulin, J. P., Maurette, P., Corcuff, J. B., Rivat, C., Chauvin, M., et al. (2002). The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesthesia and Analgesia, 94, 1263–1269, table of contents.PubMedCrossRefGoogle Scholar
  133. Leo, J. A., Tanga, F. Y., & Tawfik, V. L. (2004). Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist, 10, 40–52.CrossRefGoogle Scholar
  134. Levine, A. S., Morley, J. E., Gosnell, B. A., Billington, C. J., & Bartness, T. J. (1985). Opioids and consummatory behavior. Brain Research Bulletin, 14, 663–672.PubMedCrossRefGoogle Scholar
  135. Lidstone, S. C., & Stoessl, A. J. (2007). Understanding the placebo effect: Contributions from neuroimaging. Molecular Imaging and Biology, 9, 176–185.PubMedCrossRefGoogle Scholar
  136. Lynch, M. E. (2005). A review of the use of methadone for the treatment of chronic noncancer pain. Pain Research & Management, 10, 133–144.CrossRefGoogle Scholar
  137. Manchikanti, L., Cash, K. A., Damron, K. S., Manchukonda, R., Pampati, V., et al. (2006). Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables. Pain Physician, 9, 215–225.PubMedGoogle Scholar
  138. Mao, J. (2002). Opioid-induced abnormal pain sensitivity: Implications in clinical opioid therapy. Pain, 100, 213–217.PubMedCrossRefGoogle Scholar
  139. Mao, J. (2006). Opioid-induced abnormal pain sensitivity. Current Pain and Headache Reports, 10, 67–70.PubMedCrossRefGoogle Scholar
  140. Mao, J., Price, D. D., & Mayer, D. J. (1994). Thermal hyperalgesia in association with the development of morphine tolerance in rats: Roles of excitatory amino acid receptors and protein kinase C. The Journal of Neuroscience, 14, 2301–2312.PubMedCrossRefGoogle Scholar
  141. Martucci, C., Panerai, A. E., & Sacerdote, P. (2004). Chronic fentanyl or buprenorphine infusion in the mouse: Similar analgesic profile but different effects on immune responses. Pain, 110, 385–392.PubMedCrossRefGoogle Scholar
  142. Maxwell, J. C., Pullum, T. W., & Tannert, K. (2005). Deaths of clients in methadone treatment in Texas: 1994–2002. Drug and Alcohol Dependence, 78, 73–81.PubMedCrossRefGoogle Scholar
  143. McNicholas, T. A., Dean, J. D., Mulder, H., Carnegie, C., & Jones, N. A. (2003, January). A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU International, 91(1), 69–74.PubMedCrossRefGoogle Scholar
  144. McNicol, E., Horowicz-Mehler, N., Fisk, R. A., Bennett, K., Gialeli-Goudas, M., et al. (2003). Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review. The Journal of Pain, 4, 231–256.PubMedCrossRefGoogle Scholar
  145. McQuay, H. (1999). Opioids in pain management. Lancet, 353, 2229–2232.PubMedCrossRefGoogle Scholar
  146. McWilliams, L. A., Clara, I. P., Murphy, P. D., Cox, B. J., & Sareen, J. (2008). Associations between arthritis and a broad range of psychiatric disorders: Findings from a nationally representative sample. The Journal of Pain, 9, 37–44.PubMedCrossRefGoogle Scholar
  147. Meghani, S. H., Wiedemer, N. L., Becker, W. C., Gracely, E. J., & Gallagher, R. M. (2009). Predictors of resolution of aberrant drug behavior in chronic pain patients treated in a structured opioid risk management program. Pain Medicine, 10, 858–865.PubMedCrossRefGoogle Scholar
  148. Meldrum, M. L. (2003). A capsule history of pain management. The Journal of American Medical Association, 290, 2470–2475.CrossRefGoogle Scholar
  149. Meunier, J. C., Mollereau, C., Toll, L., Suaudeau, C., Moisand, C., et al. (1995). Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature, 377, 532–535.PubMedCrossRefGoogle Scholar
  150. Michna, E., Ross, E. L., Hynes, W. L., Nedeljkovic, S. S., Soumekh, S., et al. (2004). Predicting aberrant drug behavior in patients treated for chronic pain: Importance of abuse history. Journal of Pain and Symptom Management, 28, 250–258.PubMedCrossRefGoogle Scholar
  151. Miller, M., Barber, C. W., Leatherman, S., Fonda, J., Hermos, J. A., Cho, K., & Gagnon, D. R. (2015, April). Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Internal Medicine, 175(4), 608–615.PubMedCrossRefGoogle Scholar
  152. Moore, R. A., & McQuay, H. J. (2005). Prevalence of opioid adverse events in chronic non-malignant pain: Systematic review of randomised trials of oral opioids. Arthritis Research & Therapy, 7, R1046–R1051.CrossRefGoogle Scholar
  153. Morley, S., Eccleston, C., & Williams, A. (1999). Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain, 80, 1–13.PubMedCrossRefGoogle Scholar
  154. Mossey, J. M., & Gallagher, R. M. (2004). The longitudinal occurrence and impact of comorbid chronic pain and chronic depression over two years in continuing care retirement community residents. Pain Medicine, 5, 335–348.PubMedCrossRefGoogle Scholar
  155. National Opioid Use Guideline Group. (2010). Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. Hamilton, ON: McMaster University. Available from: http://nationalpaincentre.mcmaster.ca/opioid/cgop_a00_executive_summary.html.Google Scholar
  156. Nicholas, M. K., Molloy, A. R., & Brooker, C. (2006). Using opioids with persisting noncancer pain: A biopsychosocial perspective. The Clinical Journal of Pain, 22, 137–146.PubMedCrossRefGoogle Scholar
  157. Nickel, M. K., Lahmann, C., Muehlbacher, M., Nickel, C., Pedrosa Gil, F., et al. (2006). Change in instrumental activities of daily living disability in female senior patients with musculosceletal pain: A prospective, randomized, controlled trial. Archives of Gerontology and Geriatrics, 42, 247–255.PubMedCrossRefGoogle Scholar
  158. Noble, M., Treadwell, J. R., Tregear, S. J., et al. (2010). Long-term opioid management for chronic noncancer pain. Cochrane Database of Systematic Reviews, (1), CD006605.  https://doi.org/10.1002/14651858.CD006605.pub2.
  159. O’Brien, C. P. (Ed.). (2006). Drug addiction and drug abuse (11th ed.pp. 607–625). New York, NY: McGraw-Hill.Google Scholar
  160. O’Rourke, T. K., Jr., & Wosnitzer, M. S. (2016, October). Opioid-induced androgen deficiency (OPIAD): Diagnosis, management, and literature review. Current Urology Reports, 17(10), 76.PubMedCrossRefGoogle Scholar
  161. Office of Applied Studies SAaMHSA. (2005). Results from the 2004 national survey on drug use and health. Rockville, MD: Department of Health and Human Services.Google Scholar
  162. Ohtani, M., Kotaki, H., Sawada, Y., & Iga, T. (1995). Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. The Journal of Pharmacology and Experimental Therapeutics, 272, 505–510.PubMedGoogle Scholar
  163. Ohtani, M., Kotaki, H., Nishitateno, K., Sawada, Y., & Iga, T. (1997). Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. The Journal of Pharmacology and Experimental Therapeutics, 281, 428–433.PubMedGoogle Scholar
  164. Olsen, G. D., Wendel, H. A., Livermore, J. D., Leger, R. M., Lynn, R. K., et al. (1977). Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. Clinical Pharmacology and Therapeutics, 21, 147–157.PubMedCrossRefGoogle Scholar
  165. Paice, J. A., Penn, R. D., & Ryan, W. G. (1994). Altered sexual function and decreased testosterone in patients receiving intraspinal opioids. Journal of Pain and Symptom Management, 9, 126–131.PubMedCrossRefGoogle Scholar
  166. Pereira, J., Lawlor, P., Vigano, A., Dorgan, M., & Bruera, E. (2001). Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing. Journal of Pain and Symptom Management, 22, 672–687.PubMedCrossRefGoogle Scholar
  167. Piercefield, E., Archer, P., Kemp, P., & Mallonee, S. (2010). Increase in unintentional medication overdose deaths: Oklahoma, 1994–2006. American Journal of Preventive Medicine, 39, 357–363.PubMedCrossRefGoogle Scholar
  168. Plein, L. M., & Rittner, H. L. (2018, July). Opioids and the immune system – friend or foe. British Journal of Pharmacology, 175, 2717–2725.PubMedCrossRefGoogle Scholar
  169. Portenoy, R. K. (1996). Opioid therapy for chronic nonmalignant pain: A review of the critical issues. Journal of Pain and Symptom Management, 11, 203–217.PubMedCrossRefGoogle Scholar
  170. Portenoy, R. K., & Foley, K. M. (1986). Chronic use of opioid analgesics in non-malignant pain: Report of 38 cases. Pain, 25, 171–186.CrossRefGoogle Scholar
  171. Porter, J., & Jick, H. (1980). Addiction rare in patients treated with narcotics. The New England Journal of Medicine, 302, 123.PubMedGoogle Scholar
  172. Poulain, P., Denier, W., Douma, J., et al. (2008). Efficacy and safety of trans-dermal buprenorphine: A randomized, placebo-controlled trial in 289 patients with severe cancer pain. Journal of Pain and Symptom Management, 36, 117–125.PubMedCrossRefGoogle Scholar
  173. Raffa, R. B., Friderichs, E., Reimann, W., Shank, R. P., Codd, E. E., et al. (1992). Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. The Journal of Pharmacology and Experimental Therapeutics, 260, 275–285.PubMedGoogle Scholar
  174. Ralphs, J. A., Williams, A. C., Richardson, P. H., Pither, C. E., & Nicholas, M. K. (1994). Opiate reduction in chronic pain patients: A comparison of patient-controlled reduction and staff controlled cocktail methods. Pain, 56, 279–288.PubMedCrossRefGoogle Scholar
  175. Raphael, K. G., Natelson, B. H., Janal, M. N., & Nayak, S. (2002). A community-based survey of fibromyalgia-like pain complaints following the World Trade Center terrorist attacks. Pain, 100, 131–139.PubMedCrossRefGoogle Scholar
  176. Raphael, K. G., Janal, M. N., Nayak, S., Schwartz, J. E., & Gallagher, R. M. (2004). Familial aggregation of depression in fibromyalgia: A community-based test of alternate hypotheses. Pain, 110, 449–460.PubMedCrossRefGoogle Scholar
  177. Rasheed, A., & Tareen, I. A. (1995). Effects of heroin on thyroid function, cortisol and testosterone level in addicts. Polish Journal of Pharmacology, 47, 441–444.PubMedGoogle Scholar
  178. Rauck, R. L. (2009). What is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical review. Pain Practice, 9, 468–479.PubMedCrossRefGoogle Scholar
  179. Rauck, R. L., Potts, J., Xiang, Q., Tzanis, E., & Finn, A. (2016). Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain. Postgraduate Medicine, 128, 1–11.PubMedCrossRefGoogle Scholar
  180. Reinscheid, R. K., Nothacker, H. P., Bourson, A., Ardati, A., Henningsen, R. A., et al. (1995). Orphanin FQ: A neuropeptide that activates an opioidlike G protein-coupled receptor. Science, 270, 792–794.PubMedCrossRefGoogle Scholar
  181. Reid, M. C., Engles-Horton, L. L., Weber, M. B., Kerns, R. D., Rogers, E. L., O’Connor, P. G. (2002, Mar). Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med, 17(3), 173–9.Google Scholar
  182. Ripamonti, C., Groff, L., Brunelli, C., Polastri, D., Stavrakis, A., et al. (1998). Switching from morphine to oral methadone in treating cancer pain: What is the equianalgesic dose ratio? Journal of Clinical Oncology, 16, 3216–3221.PubMedCrossRefGoogle Scholar
  183. Risdahl, J. M., Khanna, K. V., Peterson, P. K., & Molitor, T. W. (1998). Opiates and infection. Journal of Neuroimmunology, 83, 4–18.PubMedCrossRefGoogle Scholar
  184. Rosenblum, A., Marsch, L. A., Joseph, H., & Portenoy, R. K. (2008). Opioids and the treatment of chronic pain: Controversies, current status, and future directions. Experimental and Clinical Psychopharmacology, 16, 405–416.PubMedPubMedCentralCrossRefGoogle Scholar
  185. Sacerdote, P. (2006). Opioids and the immune system. Palliative Medicine, 20(Suppl 1), s9–s15.PubMedGoogle Scholar
  186. Sacerdote, P., Manfredi, B., Mantegazza, P., & Panerai, A. E. (1997). Antinociceptive and immunosuppressive effects of opiate drugs: A structure-related activity study. British Journal of Pharmacology, 121, 834–840.PubMedPubMedCentralCrossRefGoogle Scholar
  187. Sadava, D., Alonso, D., Hong, H., & Pettit-Barrett, D. P. (1997). Effect of methadone addiction on glucose metabolism in rats. General Pharmacology, 28, 27–29.PubMedCrossRefGoogle Scholar
  188. Schieffer, B. M., Pham, Q., Labus, J., Baria, A., Van Vort, W., et al. (2005). Pain medication beliefs and medication misuse in chronic pain. The Journal of Pain, 6, 620–629.PubMedCrossRefGoogle Scholar
  189. Schmitz, R. (1985). Friedrich Wilhelm Serturner and the discovery of morphine. Pharmacy in History, 27, 61–74.PubMedGoogle Scholar
  190. Sell, L. A., Morris, J., Bearn, J., Frackowiak, R. S., Friston, K. J., et al. (1999). Activation of reward circuitry in human opiate addicts. The European Journal of Neuroscience, 11, 1042–1048.PubMedCrossRefGoogle Scholar
  191. Skurtveit, S., Furu, K., Bramness, J., Selmer, R., & Tverdal, A. (2010). Benzodiazepines predict use of opioids: A follow-up study of 17,074 men and women. Pain Medicine, 11, 805–814.PubMedCrossRefGoogle Scholar
  192. Smith, H. S. (2008). Variations in opioid responsiveness. Pain Physician, 11, 237–248.PubMedGoogle Scholar
  193. Smith, H. S., & Peppin, J. F. (2014, October 17). Toward a systematic approach to opioid rotation. Journal of Pain Research, 7, 589–608.PubMedPubMedCentralGoogle Scholar
  194. Smith, H. S., Datta, S., & Manchikanti, L. (2013). Evidence-based pharmacotherapy of chronic pain. In R. J. Moore (Ed.), Handbook of pain and palliative care. New York, NY: Springer.Google Scholar
  195. Smith, S. M., Dart, R. C., Katz, N. P., Paillard, F., Adams, E. H., Comer, S. D., Degroot, A., Edwards, R. R., Haddox, J. D., Jaffe, J. H., Jones, C. M., Kleber, H. D., Kopecky, E. A., Markman, J. D., Montoya, I. D., O’Brien, C., Roland, C. L., Stanton, M., Strain, E. C., Vorsanger, G., Wasan, A. D., Weiss, R. D., Turk, D. C., Dworkin, R. H., & Analgesic, Anesthetic, and Addiction Clinical Trials, Translations, Innovations, Opportunities, and Networks (ACTTION) Public-Private Partnership. (2013, November). Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain, 154(11), 2287–2296.PubMedPubMedCentralCrossRefGoogle Scholar
  196. Sridharan, K., & Sivaramakrishnan, G. (2018, February). Drugs for treating opioid-induced constipation: A mixed treatment comparison network meta-analysis of randomized controlled clinical trials. Journal of Pain and Symptom Management, 55(2), 468–479.PubMedCrossRefGoogle Scholar
  197. Steiner, D. J., Sitar, S., Wen, W., et al. (2011). Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: An enriched, randomized, double-blind, placebo-controlled study. Journal of Pain and Symptom Management, 42, 903–917.PubMedPubMedCentralCrossRefGoogle Scholar
  198. Stoelting, R. K. (1991). Pharmacology, physiology, & anesthetic practice. Baltimore, MD: Lippincott Williams & Wilkins.Google Scholar
  199. Sun, E. C., Dixit, A., Humphreys, K., Darnall, B. D., Baker, L. C., & Mackey, S. (2017, March 14). Association between concurrent use of prescription opioids and benzodiazepines and overdose: Retrospective analysis. BMJ, 356, j760.PubMedPubMedCentralCrossRefGoogle Scholar
  200. Tennant, F. S., Jr., Rawson, R. A., Miranda, L., & Obert, J. (1983). Outpatient treatment of prescription opioid dependence: Comparison of two methods. NIDA Research Monograph, 43, 315–321.PubMedGoogle Scholar
  201. The American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine. (2001). Definitions related to the use of opioids for the treatment of pain. Wisconsin Medical Journal, 100(5), 28–29.Google Scholar
  202. The Management of Opioid Therapy for Chronic pain Working Group. (2010). VA/DoD clinical practice guideline for management of opioid therapy for chronic pain. Washington, DC: Department of Veteran Affairs.Google Scholar
  203. Tjaderborn, M., Jonsson, A. K., Ahlner, J., & Hagg, S. (2009). Tramadol dependence: A survey of spontaneously reported cases in Sweden. Pharmacoepidemiology and Drug Safety, 18, 1192–1198.PubMedCrossRefGoogle Scholar
  204. Tracey, I., & Bushnell, M. C. (2009). How neuroimaging studies have challenged us to rethink: Is chronic pain a disease? The Journal of Pain, 10, 1113–1120.CrossRefGoogle Scholar
  205. Trescot, A. M. (2010). Review of the role of opioids in cancer pain. Journal of the National Comprehensive Cancer Network, 8, 1087–1094.PubMedCrossRefGoogle Scholar
  206. Trescot, A. M., Datta, S., Lee, M., & Hansen, H. (2008). Opioid pharmacology. Pain Physician, 11, S133–S153.Google Scholar
  207. Tsang, A., et al. (2008). Common chronic pain conditions in developed and developing countries: Gender and age differences and comorbidity with depression-anxiety disorders. The Journal of Pain, 9(10), 883–891.CrossRefGoogle Scholar
  208. Turk, D. C., Swanson, K. S., & Gatchel, R. J. (2008). Predicting opioid misuse by chronic pain patients: A systematic review and literature synthesis. The Clinical Journal of Pain, 24, 497–508.PubMedCrossRefGoogle Scholar
  209. Twycross, R. G. (1977). A comparison of diamorphine with cocaine and methadone. British Journal of Clinical Pharmacology, 4, 691–693.PubMedCentralCrossRefPubMedGoogle Scholar
  210. U.S. Department of Veterans Affairs Opioid Taper Decision Tool. https://www.pbm.va.gov/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdf. Accessed on April 27, 2018.
  211. Vadivelu, N., & Hines, R. L. (2007). Buprenorphine: A unique opioid with broad clinical applications. Journal of Opioid Management, 3, 49–58.PubMedCrossRefGoogle Scholar
  212. Vallejo, R., de Leon-Casasola, O., & Benyamin, R. (2004). Opioid therapy and immunosuppression: A review. American Journal of Therapy, 11, 354–365.CrossRefGoogle Scholar
  213. van Tulder, M. W., Ostelo, R., Vlaeyen, J. W., Linton, S. J., Morley, S. J., et al. (2000). Behavioral treatment for chronic low back pain: A systematic review within the framework of the Cochrane Back Review Group. Spine (Philadelphia, PA 1976), 25, 2688–2699.CrossRefGoogle Scholar
  214. Vanderah, T. W., Gardell, L. R., Burgess, S. E., Ibrahim, M., Dogrul, A., et al. (2000). Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. The Journal of Neuroscience, 20, 7074–7079.PubMedCrossRefGoogle Scholar
  215. Vestergaard, P., Rejnmark, L., & Mosekilde, L. (2006). Fracture risk associated with the use of morphine and opiates. Journal of Internal Medicine, 260, 76–87.PubMedCrossRefGoogle Scholar
  216. Vissers, K. C., Besse, K., Hans, G., Devulder, J., & Morlion, B. (2010). Opioid rotation in the management of chronic pain: Where is the evidence? Pain Practice, 10, 85–93.PubMedCrossRefGoogle Scholar
  217. Volkow, N. D., & McLellan, A. T. (2016, March 31). Opioid abuse in chronic pain--misconceptions and mitigation strategies. The New England Journal of Medicine, 374(13), 1253–1263.CrossRefGoogle Scholar
  218. Vowles, K. E., McEntee, M. L., Julnes, P. S., Frohe, T., Ney, J. P., & van der Goes, D. N. (2015, April). Rates of opioid misuse, abuse, and addiction in chronic pain: A systematic review and data synthesis. Pain, 156(4), 569–576.PubMedCrossRefGoogle Scholar
  219. Vuong, C., Van Uum, S. H., O’Dell, L. E., Lutfy, K., & Friedman, T. C. (2010). The effects of opioids and opioid analogs on animal and human endocrine systems. Endocrine Reviews, 31, 98–132.PubMedCrossRefGoogle Scholar
  220. Wasan, A. D., Wootton, J., & Jamison, R. N. (2005). Dealing with difficult patients in your pain practice. Regional Anesthesia and Pain Medicine, 30, 184–192.PubMedCrossRefGoogle Scholar
  221. Wasan, A., Michna, E., Greenfield, S., & Jamison, R. (2006). Interpreting urine drug tests: Prevalence of morphine metabolites to hydromorphone in chronic pain patients treated with morphine. Regional Anesthesia and Pain Medicine, 30, A-7.Google Scholar
  222. Wasan, A. D., Butler, S. F., Budman, S. H., Fernandez, K., Weiss, R. D., et al. (2009). Does report of craving opioid medication predict aberrant drug behavior among chronic pain patients? The Clinical Journal of Pain, 25, 193–198.PubMedPubMedCentralCrossRefGoogle Scholar
  223. Watkins, L. R., & Maier, S. F. (2000). The pain of being sick: Implications of immune-to-brain communication for understanding pain. Annual Review of Psychology, 51, 29–57.PubMedCrossRefGoogle Scholar
  224. Way, B. M., Taylor, S. E., & Eisenberger, N. I. (2009). Variation in the mu-opioid receptor gene (OPRM1) is associated with dispositional and neural sensitivity to social rejection. Proceedings of the National Academy of Sciences of the United States of America, 106, 15079–15084.PubMedPubMedCentralCrossRefGoogle Scholar
  225. Webster, L. R. (2010). Considering the risks of benzodiazepines and opioids together. Pain Medicine, 11, 801–802.PubMedCrossRefGoogle Scholar
  226. Webster, L. R., & Fine, P. G. (2012, April). Review and critique of opioid rotation practices and associated risks of toxicity. Pain Medicine, 13(4), 562–570.CrossRefGoogle Scholar
  227. Webster, L. R., & Webster, R. M. (2005). Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the Opioid Risk Tool. Pain Medicine, 6, 432–442.CrossRefGoogle Scholar
  228. Webster, L. R., Choi, Y., Desai, H., Webster, L., & Grant, B. J. (2008). Sleep-disordered breathing and chronic opioid therapy. Pain Medicine, 9, 425–432.PubMedCrossRefGoogle Scholar
  229. Weschules, D. J., & Bain, K. T. (2008). A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Medicine, 9, 595–612.PubMedCrossRefGoogle Scholar
  230. Wiedemer, N. L., Harden, P. S., Arndt, I. O., & Gallagher, R. M. (2007). The opioid renewal clinic: A primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Medicine, 8, 573–584.PubMedCrossRefGoogle Scholar
  231. Xie, J. Y., Herman, D. S., Stiller, C. O., Gardell, L. R., Ossipov, M. H., et al. (2005). Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. The Journal of Neuroscience, 25, 409–416.PubMedCrossRefGoogle Scholar
  232. Yilmaz, B., Konar, V., Kutlu, S., Sandal, S., Canpolat, S., et al. (1999). Influence of chronic morphine exposure on serum LH, FSH, testosterone levels, and body and testicular weights in the developing male rat. Archives of Andrology, 43, 189–196.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations